Therapeutic Solutions International Inc. (OTCMKTS:TSOI) is up 55% this week. The company has announced findings and a patent submission describing JadiCell adult stem Cells’ superior ability relative to other stem cells in stimulating new brain cells production in animal models of inflammation. The new brain cells production is called “neurogenesis,” an active research area for the company.
Chief Medical Officer James Veltmeyer stated that they realized that increasing double-stranded RNA doses mimicking viral prompted inflammation connected with reduced neurogenesis as expected. Surprisingly, only the company’s JadiCells could stimulate neurogenesis under inflammation conditions of all stem cells evaluated.The findings demonstrate JadiCell’s potential in patients with severe COVID-19 and fighting the long-term impact of the virus.
The company, which has the only IND submission for chronic traumatic encephalopathy treatment, has received approval from the FDA to continue studies evaluating JadiCell stem cells in treatment o COVID-19 induced lung failure. The company’s JadiCEll showed superiority against other types of stem cells. With JadiCell’s potential, investors should watch TSOI.
On Wednesday, TSOI stock went up 2.52% at $0.0610 with more than 15.40 million shares, compared to its average volume of 8.66 million shares. The stock has moved within a range of $0.0595 – 0.0640 after opening the trade at $0.060.